Jiangsu Hengrui Medicine
600276.SS
#460
Rank
S$57.83 B
Marketcap
$9.07
Share price
-1.68%
Change (1 day)
10.46%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): S$1.33 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are S$3.88 Billion. , an increase over its 2023 earnings that were of S$0.86 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 S$1.30 B50.69%
2023 S$0.86 B11.4%
2022 S$0.77 B-13.65%
2021 S$0.90 B-34.21%
2020 S$1.37 B15.95%
2019 S$1.18 B33.03%
2018 S$0.88 B20.89%
2017 S$0.73 B23.89%
2016 S$0.59 B11.21%
2015 S$0.53 B39.5%
2014 S$0.38 B20.61%
2013 S$0.31 B11.46%
2012 S$0.28 B29.7%
2011 S$0.21 B31.16%
2010 S$0.16 B27.92%
2009 S$0.13 B5.8%
2008 S$0.12 B79.95%
2007 S$68.64 M32.89%
2006 S$51.65 M38.19%
2005 S$37.38 M21.56%
2004 S$30.75 M13.95%
2003 S$26.98 M38.06%
2002 S$19.54 M